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ABSTRACT
Background & objectives: The present study aimed to systematically quantify the well known risk of severe
dengue during secondary infection in literature and to understand how epidemiological mechanisms of enhancement
during the secondary infection influence the empirically estimated risk of severe dengue by means of mathematical
modeling.
Methods: Two conditional risks of severe dengue, i.e. symptomatic illness and dengue hemorrhagic fever (DHF)
or dengue shock syndrome (DSS), given secondary infection were explored based on systematically searched
prospective studies. A two-strain epidemiological model was employed to simulate the transmission dynamics of
dengue and to identify the relevant data gaps in empirical observations.
Results: Using the variance-based weighting, the pooled relative risk (RR) of symptomatic illness during secondary
infection was estimated at 9.4 [95% confidence interval (CI): 6.1–14.4], and similarly, RR of DHF/DSS was
estimated to be 23.7 (95% CI: 15.3–36.9). A variation in the RR of DHF/DSS was observed among prospective
studies. Using the mathematical modeling technique, we identified the duration of cross-protective immunity as
an important modulator of the time-dependent behaviour of the RR of severe dengue. Different epidemiological
mechanisms of enhancement during secondary infection yielded different RR of severe dengue.
Interpretation & conclusion: Optimal design of prospective cohort study for dengue should be considered,
accounting for the time-dependence in the RR during the course of dengue epidemic. It is critical to statistically
infer the duration of cross-protective immunity and clarify how the enhancement influences the epidemiological
dynamics during secondary infection.
Key words Dengue; dengue hemorrhagic fever; enhancement; epidemiology; Flaviviridae; interference; mathematical model;
susceptibility
INTRODUCTION
Dengue fever (DF), dengue hemorrhagic fever (DHF)
and dengue shock syndrome (DSS) are caused by dengue
virus (DENV) that belongs to the family of Flaviviridae,
consisting of four closely related serotypes1. The virus is
transmitted by mosquito vector Aedes spp including Aedes
aegypti and Ae. albopictus (Diptera: Culicidae), contrib-
uting to high disease burden in tropical and sub-tropical
areas where the vectors are abundant2. Over the decades,
the geographic area with ongoing DENV transmission has
been magnified3. Although the pathogenesis of “severe
dengue”, namely, the symptomatic infection, DF, DHF
and DSS (especially the last two) has yet to be fully clari-
fied, a number of apparent risk factors for DHF and
DSS including secondary infection with heterologous
strain4–5 and different virulence and susceptibility6–8 has
been reported in literature.
The elevated risk of severe dengue during secondary
infection (as compared to primary infection) has been
originally identified from epidemiological observations9.
During the secondary infection, the so-called antibody
dependent enhancement (ADE) is known to be observed
and is considered responsible for the pathophysiological
development of DHF or the vascular permeability syn-
drome4. While a number of prospective studies have been
conducted to observe the elevated risk of severe dengue
during secondary (and tertiary) infection, and also a re-
view study has taken place elsewhere10, we have yet to
understand the link between ADE (or other biological
mechanisms of severe dengue) and the data generating
process of epidemiologically observed severe dengue.
However, epidemiological mechanisms of severe dengue
during secondary infection have yet to be clarified: it has
not been fully understood how the enhancement influ-
ences the epidemiological dynamics, e.g. is severe den- J Vector Borne Dis 51, September 2014 154
gue caused by: (i) simply increasing the conditional prob-
ability of severe clinical manifestations (given infection);
(ii) increasing susceptibility of host who was previously
exposed to other serotype(s); or (iii) delaying recovery
from infection during secondary infection and extending
infectious period?11 To appropriately describe and inter-
pret the epidemiology of severe dengue, epidemiological
studies should be designed based on a firm understand-
ing of the transmission dynamics.
Whereas, the causal relationship between DHF/DSS
and secondary infection has been well demonstrated in
literature, it is fruitful to understand how the secondary
infection leads to an increase in severe dengue in an epi-
demiological manner. The purposes of the present study
are two-folds. First, we aimed to quantitatively analyze
the known “risks” of severe dengue during secondary in-
fection by systematically reviewing prospective obser-
vational studies at a population level, thereby character-
izing the elevated risks of severe dengue in literature.
Second, we exploited a simple mathematical model
with two interacting serotypes (and enhancement),
simulating epidemics caused by two serotypes and
measuring differential impact of enhancement on the rela-
tive risk estimates of severe dengue during secondary in-
fection.
MATERIAL & METHODS
The present study consists of two major steps, (i) a
systematic review and meta-analysis of published litera-
ture on severe dengue; and (ii) mathematical modeling
and scenario analysis that intend to clarify the data gaps
and help consider appropriate study design in the future.
As for the former, this systematic review and meta-analy-
sis was conducted in accordance with the Preferred Re-
porting Items for Systematic Reviews and Meta-Analy-
ses (PRISMA) statement12.
Search strategy
Prospective studies containing data on enhancement
were retrieved from the Medline (PubMed) and Web of
Science electronic databases on 1 March 2013. We used
the following free text search terms in ‘All fields’: ‘den-
gue’, ‘enhancement’ OR ‘secondary infection’, ‘cohort’
OR ‘prospective study’ and their combinations.
The search was limited to studies published after 1984,
i.e. subsequent to the first long-term dengue prospective
cohort study in Thailand5. Additional relevant studies
identified by authors were manually retrieved from other
databases.
Study selection
To select studies, all titles, identified by the search
strategy, were screened by two authors independently
(K.M. and H.N.). Subsequently, abstracts of only relevant
titles were further screened for review of eligibility, and
articles were selected for closer examination of full-text
if it turns out to be a prospective (cohort) study of den-
gue. For clarity, retrospective and clinical studies (includ-
ing prospective ones with recruitment only at medical
facilities) were excluded. Eligible articles must explicitly
define secondary infection (e.g. having been confirmed
as immune to a single serotype before an epidemic of
the other serotype) as well as primary infection (e.g.
having been confirmed as fully susceptible before an
epidemic). Multiple reports of the same dataset (i.e.
the same geographic area at the same time) were jointly
assessed.
Ascertainment of primary infection and secondary
infection
During the systematic review, we focused on two risks
of severe dengue during secondary infection, including
the conditional risk of symptomatic illness and the con-
ditional risk of DHF (inclusive of DSS), both given DENV
infection. Relative risk (RR) was calculated as the pro-
portion of severe dengue during secondary infection di-
vided by the same proportion during primary infection.
DENV infection was identified by virologic testing or
serologic evidence of infection. Primary and secondary
infections have been defined as infections among those
with previous sero-negative and sero-positive states prior
to the infection event, respectively. For simplicity, we
discarded the serotype information and the sequence of
infections with different serotypes.
Data extraction
We extracted the information regarding primary/sec-
ondary infection, asymptomatic/symptomatic infection
and DHF/DSS. If reported, we also analyzed additional
results from the serological survey (including the timing
of the survey relative to the epidemic time), absenteeism
survey, and attendance to fever clinic. All the datasets
were summarized in a standardized form.
Meta-analysis
RRs of the above mentioned two outcomes were ex-
tracted from each eligible study, and subsequently, the
pooled estimate was obtained. We used the inverse of the
variance of RR as the weight of each study when calcu-
lating the pooled estimate. As an alternative method, we 155 Mizumoto et al: Severe dengue during secondary infection
also computed the pooled effect size by employing the
random effects model. Statistical heterogeneity was as-
sessed by Q statistic as well as I2 statistic (representing
the extent of the degree of variation). All statistical data
were analyzed using a statistical software JMP version
9.0.0 (SAS Institute Inc., Cary, NC, USA).
Modeling method
As a second part of the present study, we employed a
deterministic epidemiological model that describes the
time-dependent transmission dynamics of dengue with
two distinct serotypes. Specifically, we tackled two ques-
tions: (i) how the timing of observation influences the
estimate of effect size (i.e. RR of severe dengue during
secondary infection) during the course of epidemics, and
(ii) how different epidemiological scenarios with differ-
ent mechanisms of enhancement influence the RR esti-
mate. As for the former, we computed the RR of severe
dengue during secondary infection by varying the mean
duration of cross-protective immunity and the time-lag
between the invasion of one serotype and that of the other
serotype. For the latter question, we compared the dy-
namics under three hypothetical scenarios, i.e. the sce-
nario in which: (a) the conditional risk of severe dengue
is elevated given secondary infection, (b) susceptibility
during secondary infection is increased, and (c) the dura-
tion of infectious period during secondary infection is
extended.
Figure 1 shows the compartment that we used to com-
pute the epidemiological dynamics of dengue. Each state
of infection is represented by single compartment in
Fig. 1 with arrows indicating the direction and rate of
transition. Since, we considered epidemics in a short-time
scale, the background demography of human host, like
birth and death, was ignored. First and second letters for
each compartment stand for the state of infection with
Fig. 1: Transmission dynamics of dengue with two serotypes. A compartmental model is employed. First and second letters for each compartment
stand for the state of infection with respect to serotype 1 and serotype 2, respectively. S stands for susceptible, I stands for infectious, R
represents recovered and immune, and W represents protected state due to cross-protective immunity. Thus, for example, RI represents
the host who recovered from infection with serotype 1 while being infectious with serotype 2. The transition rates are written on the
arrows. λi, the force of infection with serotype i (for i = 1, 2); 1/γ, the mean duration of infectious period; 1/δ, the mean duration of cross-
protective immunity; η, the conditional hazard of severe dengue given dengue virus infection; α1, relative susceptibility during secondary
infection compared to primary infection; 1/α2, relative infectious period during secondary infection compared to primary infection;
κ, relative conditional hazard of severe dengue during secondary infection given dengue virus infection. J Vector Borne Dis 51, September 2014 156
serotype 1 and serotype 2, respectively. Although, there
are four distinct serotypes of dengue virus in reality, we
considered only two theoretical serotypes in modeling
exercise, because our outcome (i.e. RR of severe dengue
during secondary infection) for a two-serotype setting
mirrors that of a realistic four-serotype setting. S
stands for susceptible, I stands for infectious, R repre-
sents recovered and immune state, and W represents
a protected state due to a short-lasting cross-protective
immunity (i.e. when a host experiences infection with a
single serotype, it is assumed that the infected host is
protected from infection with other serotypes for a short
period of time13–14). Thus, for example, RI represents the
host who recovered from infection with serotype 1 while
being infectious with serotype 2. It should be noted that
we ignored the dynamics of mosquito vector in the fol-
lowing model (while incorporating the delay in second-
ary transmission due to the extrinsic incubation period
into the model by extending the generation time), because
the detailed population dynamics of mosquitoes is out of
the scope of the present study and we focus on the natural
history of dengue in the human host.
Let 1/γ  be the mean duration of infectious period and
1/δ be the mean duration of cross-protective immunity.
It should be noted that for simplicity, we assumed that all
parameters are identical between serotypes (i.e. the dy-
namics is symmetric). The transmission dynamics is de-
scribed by the system of ordinary differential equations:
1/α2 reflect the enhancement in epidemiological dynam-
ics, each interpreted as follows: α1, the relative suscepti-
bility during secondary infection compared to primary
infection, and 1/α2, the relative infectious period during
secondary infection compared to that during primary in-
fection. Let η be the conditional hazard of severe dengue
given infection. Cumulative numbers of severe dengue
during primary and secondary infections are calculated
as:
... (3)
where, κ is the conditional relative hazard of severe den-
gue given secondary infection. Let Y(t) represent the num-
ber of hosts who have experienced only primary infec-
tion, i.e.
Y (t) = N – SS(t)–RI(t) – IR(t) – RR(t), ... (4)
where, N represents the total population size which is as-
sumed to be a constant. Considering that an epidemio-
logical study samples the data from the population at the
most recent time T, the relative risk estimate that we ob-
tain is calculated as:
     ... (5)
The parameter values that we used for numerical so-
lutions are shown in Table 113,15–17.
We examined the sensitivity of RR in (5) to model
parameters and initial conditions for two different sce-
narios. In both scenarios, we consider an epidemic in the
population of N = 1,000,000 individuals in which N-1 are
initially fully susceptible and 1 is newly infected with
serotype 1 at time t = 0. In the first scenario, it is assumed
that secondary infection induces only the elevated risk of
severe clinical manifestations at 10 times as compared
with that during primary infection, and the mean dura-
tion of cross-protective immunity is allowed to vary from
0 to 360 days. During the course of the epidemic, an in-
fected individual with serotype 2 is introduced to the com-
munity at variable timings; before the epidemic peak (at
Day 50), nearby the epidemic peak (Day 72) and during
the declining phase of the epidemic (Day 100). We can
then measure how r(t) varies as a function of epidemic
time. In the second scenario, the epidemiological mecha-
nism of enhancement is varied, while the time to intro-
duce a single infected individual with serotype 2 is fixed
at Day 72. We can measure r(t) as a function of time for
  ... (1)
where, λi represents the force of infection with serotype
i(for i = 1 or 2) (or the rate at which susceptible individu-
als acquire infection with serotype i) calculated as:
... (2)
where, β scales the rate of transmission. Other two pa-
rameters in system (1) during secondary infection, α1 and 157 Mizumoto et al: Severe dengue during secondary infection
three possible types of enhancement, i.e. (a) κ = 10, (b)
α1 = 10, or (c) 1/α2 = 10. We also examined the same
types of enhancement with different level— (a) κ = 5, (b)
α1 = 5, or (c) 1/α2 = 5. Subsequently, we investigated
how r(t) is scaled by κ, α1 and 1/α2 at the end of the epi-
demics of both serotypes. A differential equation solver,
Berkeley Madonna version 8.0.1 (Robert Macey and
George Oster, CA, USA) was used to numerically simu-
late the epidemics.
RESULTS
Reviewed literature
Of the 46 titles that were initially identified, 37 ab-
stracts were assessed for eligibility, of which 22 were ex-
cluded. In total, 15 full length articles were assessed for
eligibility (Fig. 2). Of these, eight studies were
determined to be eligible and included in this systematic
review (Table 2)5, 18–25. One of the eight studies was
split into two original research articles in a single volume
of a periodical21–22, and thus, hereafter we combined two
articles into a single study. Of the excluded 22 abstracts,
20 articles were clinical studies (e.g. conducted
at healthcare facilities), one article was retrospective
study, and one article was a mathematical modeling
study. Of the excluded seven full length reports, six
articles were clinical studies enrolling participants at
hospital settings only26–31 and one article was a retrospec-
tive study32.
Secondary infection and severe dengue in literature
Of the included eight cohort studies, five studies re-
ported RR of symptomatic illness and DHF/DSS during
secondary infection compared to primary infection. The
reported estimates are summarized in Fig. 3 with the RR
of symptomatic illness and DHF/DSS ranging from 1.9
to 14.3 and from 1.4 to 58.1, respectively. There have
been multiple reports that measured the association be-
tween secondary infection and DSS, but DSS during pri-
mary infection was too scarce and did not permit precise
calculation of RR. For this reason, we grouped DHF and
DSS into a single category in all of the following results.
Using the variance-based method, the pooled estimate of
RR of symptomatic illness during secondary infection was
9.4 [95% confidence interval (CI): 6.1–14.4], and simi-
larly, RR of DHF/DSS was 23.7 (95% CI: 15.3–36.9).
The pooled estimates using the random effects model were
not significantly different: RR of symptomatic illness and
DHF/DSS were 5.9 (95% CI: 0.99–35.7) and 15.2 (95%
CI: 1.7–137.1), respectively, although the lower bound
for symptomatic illness was slightly below unity. A very
little heterogeneity was identified for the symptomatic
Fig. 2: Flow diagram of study selection.
Table 1. Parameter values for an epidemiological model of dengue
Parameter’s interpretation Notation Baseline value Reference
Mean duration of cross-protective immunity 1/δ 180 (days) [13]
Relative susceptibility during secondary infection α1 >1 (See main text) [assumed]
compared to primary infection
Relative infectious period during secondary infection 1/α2 >1 (See main text) [assumed]
compared to primary infection
Mean duration of infectious period 1/γ 10 (days) [15]
Basic reproduction number of serotype iR i 3* [16–17]
Relative conditional hazard of severe dengue during secondary κ >1 (See main text) [assumed]
infection given infection
Conditional hazard of severe dengue given infection η 1.2 × 10-2 [assumed]
Force of infection with serotype i λi (As calculated in the main text)
*The transmission coefficient, β was calculated from the relationship βi = Riγ. We ignored the serotype-specificity (e.g. difference in γ) in
simulations. J Vector Borne Dis 51, September 2014 158
illness (Fig. 3a) with Q = 3.8 and I2 = 0%, while a varia-
tion in the RR of DHF/DSS was seen (Fig. 3b) with
Q = 13.1 and I2 = 69.4%.
Table 2 shows additional information of our interest
during secondary infection in eight cohort studies. Of the
eight studies, routine surveillance of absenteeism was con-
ducted in five studies (62.5%), while the attendance to
fever clinic was observed in seven studies (87.5%). As
for the timing of serological survey relative to the epi-
demic, four studies (37.5%) obtained samples “during and
after epidemic” and three studies (37.5%) did so “after
epidemic” only. The time lag from the epidemic to sero-
logical survey was most commonly <3 months in five
studies (62.5%).
Simulated epidemics with two serotypes
Figure 4 shows the relative risk estimates (of severe
dengue which can be interpreted as symptomatic illness,
DHF/DSS or other form of severe manifestation) by vary-
ing the time to introduce serotype 2 during the course of
the serotype 1 epidemic and also by varying the mean
duration of cross-protective immunity. It is remarkable
that the RR varies as a function of time, and it reaches to
the stable state only after the end of epidemics of both
serotype 1 and 2. Figures 4 (a), (c) and (e) indicate that
the timing to introduce serotype 2 has only limited
impact on the time-dependency of the RR. However,
Figs. 4 (b), (d) and (f) clearly demonstrate that the time-
dependent behaviour of RR, r(T) is sensitive to the dura-
tion of cross-protective immunity.
In Fig. 5, we examined r(T) for three possible types
of enhancement, i.e. when (a) the conditional risk of se-
vere illness was elevated, (b) susceptibility to secondary
infection was elevated, and (c) the infectious period dur-
ing secondary infection is extended. Three different as-
pects are notable. First, as can be expected from Fig. 4,
the time-dependent behaviour of r(T) is sensitive to the
duration of cross-protective immunity. Second, although
the enhancement types (a) and (c) lead to similar equilib-
rium at the end of the epidemic of both serotypes, it is
remarkable that the enhancement in susceptibility finds a
rather different equilibrium value. That is, although the
increase in susceptibility has been a common assumption
(or interpretation) for describing the epidemiological
mechanism of enhancement in various published stud-
ies11, 33, the elevated susceptibility does not lead to an
increase in r(T) and even leads to the relative risk below
unity. Third, for all three types of enhancement, the equi-
librium value of the relative risk is different from the scale
of the enhancement in the corresponding parameter. For
instance, Figs. 5 (a), (c) and (e) magnified one of param-
eters by 10 times, but the equilibrium r(T) value takes
approximately 5 for (a) and (c), and 1 for (b), respec-
tively. Figures 5 (b), (d) and (f) multiply 5 to one of
the parameters, but r(T) is stable approximately at 3.5 for
(a) and (c), and 1 for (b), respectively. Figure 6 shows
the relationship between r(T) value at an equilibrium
(i.e. at the end of epidemics of both serotypes) and the
relative change in one of the parameters that were
assumed to govern the enhancement during secondary
infection. Again, it is remarkable that an increase in
susceptibility does not lead to an observation of increase
in the relative risk of severe dengue during secondary
infection.
Table 2. Available epidemiological information other than symptomatic illness and dengue hemorrhagic fever and the timing of serological
survey in eight selected prospective studies of dengue virus infection
Country First author Absenteeism* Attendance to Relative timing† Duration‡
reference fever clinic**
Thailand Sangkawibha et al5 No Yes After epidemic Seemingly < 3 months
Thailand Burke et al18 Yes Partly yes During and after epidemic Seemingly < 3 months
Myanmar Thein et al19 No Yes After epidemic NA
Indonesia Graham et al20 No Yes During epidemic 0 month
Thailand Endy et al21–22 Yes Partly yes During and after epidemic Seemingly < 3 months
Indonesia Porter et al23 Yes No During and after epidemic < 3 months
Nicaragua Balmaseda et al24 Yes Partly yes After epidemic Seemingly < 3 months
Thailand Endy et al25 Yes Partly yes During and after epidemic Seemingly < 3 months
*Conducted the survey of children’s absenteeism during dengue epidemic; **Conducted the survey of febrile individuals (e.g. enforcing people
to visit outpatients upon onset of fever); †The timing of serological sampling relative to the epidemic; ‡The time lag between the end of epidemic
and serological survey. 159 Mizumoto et al: Severe dengue during secondary infection
DISCUSSION
The present study combined two epidemiological
approaches, i.e. systematic review and mathematical
modeling, to understand known epidemiological risks of
severe dengue during secondary infection and clarify rel-
evant data gaps and pitfalls in measuring the RR of se-
vere dengue during secondary infection by means of math-
ematical modeling. In the systematic review and
meta-analysis, we examined two common outcomes of
severe dengue, namely the RR of symptomatic illness and
DHF/DSS during secondary infection. A variation in the
estimated RR of DHF/DSS was observed between stud-
ies. In addition, we identified that many serological sur-
veys took place during or shortly after an epidemic sea-
son. Using an epidemiological model, we identified the
duration of cross-protective immunity as an important
modulator of the time-dependent behaviour of the RR of
severe dengue. Differently assumed epidemiological
mechanisms of enhancement during secondary infection
Fig. 3: Relative risk of: (a) symptomatic illness, and (b) dengue hemorrhagic fever or dengue shock syndrome during secondary infection. Note
that logarithmic scale is employed for the horizontal axis, i.e. relative risk =1 corresponds to LN (relative risk = 0). The whiskers extend
out to lower and upper 95% confidence intervals. Pooled estimate using the inverse of the variance of RR is shown as the diamond with
both ends extending to the lower and upper 95% confidence intervals. J Vector Borne Dis 51, September 2014 160
Fig. 4: Estimated relative risk of severe dengue during secondary infection as a function of time. Sensitivity of relative risk (RR) of severe
dengue (e.g. DHF/DSS) to different lengths of cross-protective immunity following a primary infection (1/δ) and different time lags
between the invasion of 1 serotype and that of the other serotype (tin). Figures (a), (c) and (e) examine the sensitivity of RR to different
mean durations of cross-protective immunity (1/δ ranging from 0 to 360) with the introduction of second serotype at tin = 50 days, tin =
72 days and tin = 100 days, respectively, from the start of the epidemic with serotype 1. Figures (b), (d) and (f) examine the sensitivity of
RR to different time lags between the invasion of one serotype and that of the other serotype (tin ranging from 50 to 100) with the fixed
mean durations of cross-protective immunity at 1/δ = 0 day, 180 days and 360 days, respectively. For all scenarios, it is assumed that
secondary infection induces only the elevated risk of severe clinical manifestations at 10 times as compared with during primary
infection). 161 Mizumoto et al: Severe dengue during secondary infection
Fig. 5: Estimated relative risk of severe dengue during secondary infection with varying mechanisms of enhancement. Each Figure multiplies
one of parameters that are considered to govern the enhancement by a factor of 10 [Figs. (a), (c) and (e)]; and 5 [Figs. (b), (d) and (f)].
In each Figure, there are three parameters to reflect the enhancement in epidemiological manners, i.e. the relative hazard of severe
dengue given secondary infection (“Severe infection”), the relative susceptibility to secondary infection (“Susceptibility”) and the
relative duration of infectious period given secondary infection (“Infectious period”). The mean duration of cross-protective immunity
(1/δ) is also varied, i.e. 1/δ = 0 day (a and b), 180 days (c and d), and 360 days (e and f). The epidemic time (i.e. the time since
introduction of a single index case infected with serotype 1) to introduce a single infected individual with serotype 2 is fixed at Day 72. J Vector Borne Dis 51, September 2014 162
yielded different estimates of the RR, and in particular,
we observed an unexpectedly small RR when the suscep-
tibility of once-infected host was elevated during second-
ary infection.
There are two important lessons that should be learnt
from the present study. First, our finding indicates a criti-
cal need to consider the optimal design of prospective
study, accounting for the time-dependent aspect of the risk
during the course of epidemics. As we have shown, the
duration of cross-protective immunity is likely a key epi-
demiological driver to regulate appropriate time frame of
empirical observations, and the statistical inference of the
duration as well as other natural history is deemed essen-
tial to understand the epidemiological dynamics of den-
gue15, 34–35. Second, it is critical to clarify how the en-
hancement mechanism during secondary infection
influences the epidemiological dynamics. In particular, it
should be noted that a common assumption of enhance-
ment, i.e. the increased susceptibility, was demonstrated
to be inconsistent with the elevated RR of DHF/DSS dur-
ing secondary infection. The clarification on the mecha-
nism of enhancement calls for a specialized design of
empirical observations that permit us to measure the mecha-
nism directly, e.g. by using individual-based observational
research design with a possibility to deal with the condi-
tional risk of enhancement given DENV infection (e.g.
household-based study). While various mathematical
models have been devised to discuss the dengue control
including vaccination policy36–39, it is vital to address the
above mentioned point to bridge the gap between the
empirically observed idea (e.g. elevated RR of DHF/DSS
during secondary infection) and model assumptions.
Three limitations should be noted. First, our system-
atic review ignored strain-specific characteristics (e.g.
different virulence) and we also combined the data ignor-
ing all other aspects of observations including geographic
location, ethnicity and background health status. The risks
of symptomatic infection and severe dengue are known
to depend on age40–41. Moreover, the diagnostic criteria
of DF and DHF could also be different by study42. Nev-
ertheless, these should not be regarded as a serious limi-
tation, because the known risk factors have been already
identified as independent predictors of severe dengue and
would not alter our main results (i.e. accounting for these
risk factors would only contribute to stratifying the risks
by each individual attribute). Second, our mathematical
model rested on simple assumptions with two serotypes
only. Homogeneously mixing assumption was employed
with a symmetric structure of natural history, and hetero-
geneous risks including mosquito dynamics were ignored.
People were assumed to be fully susceptible at time 0,
but usually it is the case that we observe cross reactions
between different viruses in Flaviviridae (e.g. Japanese
encephalitis virus). Third, while we identified the impor-
tance to account for the time-dependence and clarify the
epidemiological mechanism of enhancement, the epide-
miological determinants of dengue transmission have yet
to be exhaustively identified, and epidemiologists will have
to face many other regulators in empirical observations.
In summary, our study suggested that the duration of
cross-protective immunity should be estimated from em-
pirical datasets and also emphasized that the epidemio-
logical dynamics of enhancement during secondary in-
fection should be appropriately quantified. Clarifications
on these points will help specify optimal study design of
dengue in the future. Despite our simplistic approach, we
believe that the combination of systematic review and
mathematical modeling successfully identified an addi-
tional crucial element of severe dengue in epidemiologi-
cal observations43.
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